Table 3.
General characteristics of all patients with adrenal insufficiency and in patients treated with conventional treatment and dual-release hydrocortisone treatment at baseline.
| Patients with adrenal insufficiency (N = 30) |
Conventional treatment (N = 15) |
DR-HC treatment (N = 15) |
p* | |
|---|---|---|---|---|
| Subjects (%) | Subjects (%) | Subjects (%) | ||
| Gender Male |
18 (60%) | 8 (53.3%) | 10 (66.7%) | 0.723 |
| Female | 12 (40%) | 7 (46.7%) | 5 (33.3%) | |
| Isolated primary adrenal insufficiency | 21 (70%) | 12 (80%) | 9 (60%) | 0.239 |
| Thyroid autoimmune disease | 3 (10%) | 2 (13.3%) | 1 (6.6%) | 0.546 |
| Celiac disease | 8 (26.6%) | 5 (33.3%) | 3 (20%) | 0.418 |
| Type 1 diabetes mellitus | 1 (3.3%) | 1 (6.6%) | 0 | 0.331 |
| Mean ± SD | Mean ± SD | Mean ± SD | ||
| Mean equivalent dose of hydrocortisone (mg/day) | 22.4 ± 5.77 | 23.4 ± 5.42 | 22.7 ± 6.21 | 0.258 |
| Age (years) | 40.3 ± 19.3 | 43.3 ± 18.9 | 37.8 ± 19.5 | 0.203 |
| BMI (kg/m2) | 25.4 ± 5.86 | 24.3 ± 3.47 | 24.1 ± 4.17 | 0.363 |
| Waist circumference (cm) | 95.8 ± 13.9 | 95.9 ± 12.3 | 96.5 ± 10.9 | 0.696 |
| Na (mmol/L) | 139.2 ± 4.8 | 139.6 ± 4.1 | 138.9 ± 5.41 | 0.573 |
| K (mmol/L) | 4.6 ± 0.53 | 4.67 ± 0.59 | 4.54 ± 0.42 | 0.628 |
| Total cholesterol (mmol/L) | 5.2 ± 1.21 | 4.83 ± 1.1 | 5.21 ± 1.21 | 0.165 |
| HDL cholesterol (mmol/L) | 1.41 ± 0.47 | 1.35 ± 0.49 | 1.38 ± 0.48 | 0.403 |
| Triglycerides (mmol/L) | 1.68 ± 0.94 | 1.43 ± 0.88 | 1.46 ± 0.99 | 0.476 |
| LDL cholesterol (mmol/L) | 3.04 ± 1.13 | 2.71 ± 1.11 | 2.78 ± 1.01 | 0.114 |
| HbA1c (mmol/moL) | 42.1 ± 0.8 | 42 ± 0.85 | 41 ± 0.75 | 0.685 |
| Fasting glycemia (mmol/L) | 4.95 ± 2.03 | 4.96 ± 0.79 | 5.07 ± 0.95 | 0.277 |
| C-reactive protein (mg/L) | 4.23 ± 2.75 | 4.45 ± 2.25 | 4.02 ± 3.25 | 0.121 |
| Erythrocyte sedimentation rate (mm) | 12.3 ± 8.72 | 11.9 ± 9.87 | 12.8 ± 7.59 | 0.791 |
| Fibrinogen (mg/dL) | 315.6 ± 87.6 | 260 ± 156.7 | 359.2 ± 76.6 | 0.179 |
| Neutrophil/lymphocyte ratio | 1.49 ± 0.7 | 1.41 ± 0.71 | 1.56 ± 0.69 | 0.104 |